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Paclitaxel is an established chemotherapy drug, targeting: breast, ovarian, bladder, 
prostate, skin, esophageal and non-small cell lung cancers - the conditions that 
affected more than 25000 Singaporeans in 2010 – 2014. One of the side effects of 
paclitaxel treatment is neurotoxicity, which may lead to Paclitaxel-Induced 
Peripheral Neuropathy (PIPN). Paraesthesia, tingling and numbness symptoms 
from PIPN may result in dose reduction or even premature ending of the life-saving 
anti-cancer therapy. Nerves with long axons are more sensitive to paclitaxel’s 
toxicity and this phenomenon can be attributed to the fact that long axons are more 
sensitive to the dysregulation of mitochondrial dynamics. This investigation was 
carried out with the use of a novel mitochondrial dual-labelling method, by utilising 
the unique advantage a compartmentalised neuron culture system has from the 
fluidic and spatial isolation of the chambers containing the proximal and distal 
portions of the neurons exclusively. It was found that Fluocinolone Acetonide (FA), 
a synthetic hydrocortisone derivative, induced significant anterograde trafficking 
of proximal mitochondria (PM) engagement into distal axons as a potential 
neuroprotective mechanism against PIPN. This phenomenon is interpreted to 
mitigate the damage to the distal mitochondria (DM) population and consequently 
protect the axons from neurodegeneration. Mitochondria dynamics were further 
characterised by means of anterograde and retrograde velocity, as well as the 
proportion of motile to stationary mitochondria.  FA treatment recovered most of 
the paclitaxel-induced neurotoxic changes in mitochondria dynamics suggesting 
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that its neuroprotective mechanism involved the drug-induced engagement and 
rescue of the mitochondria network.   
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The onset of cancer is a debilitating condition. Anticancer therapies - 
chemotherapy, radiotherapy, surgery, immunotherapy or other drug related 
treatments - cause side effects that further reduce the patient’s quality of life. 
Paclitaxel (Taxol®; PTX) is one of the most commonly used chemotherapy drugs. 
It is an antineoplastic agent targeting ovarian, breast, prostate, lung, skin and 
esophageal cancers [1, 2]. The unwanted effect of PTX is neurotoxicity, leading to 
peripheral neuropathy. The onset of this condition might result in the tapering off 
PTX doses or even complete termination of the treatment due to the acute 
symptoms triggered by the progression of the neuropathy in the distal extremities 
[3-6]. The incidence of chemotherapy induced peripheral neuropathy (CIPN) is as 
high as 60% in PTX-treated patients  [7], which translates to 462 000 people in the 
United States of America alone [8]. The current approaches to address CIPN are 
limited to either lowering the chemotherapy drug dosage or palliative symptomatic 
treatment of the neuropathic pain [9,10].  
Paclitaxel is a taxane family drug derived from the Pacific yew tree bark [11] that 
induces microtubule stabilisation within the cell. Its anti-cancer properties stem 
from arresting cell division [12]. PTX inhibits Cdc20 and activates the mitotic 
checkpoint responsible for chromosomal missegregation  [2]. Unattached 
kinetochores lead to premature ubiquitination-mediated degradation of cyclin B. 
The cell then becomes arrested in the mitotic phase and subsequently undergoes 




regimens, especially with platinum-based drugs or vinkyl alkaloids. When applied 
together, these drugs have synergistic effects by activating alternative pathways 
towards apoptosis of targeted cancer cells during the mitotic stabilisation phase 
[12].  
PTX-induced peripheral neuropathy (PIPN) has been reported to cause a loss of 
sensation of the lower extremities (e.g. weakness in the foot muscles as well as 
reduced ankle and deep tendon reflexes) in up to 20% of patients [6], but the PIPN 
incidence can be underestimated, as it is primarily self-reported [4, 6]. The onset of 
neurodegeneration is often not apparent until nerve damage becomes significant 
[14]. Although extensively studied, the exact biological mechanisms behind PIPN 
remain inconclusive. The current understanding suggests two non-exclusive 
mechanisms: the indirect effects of PTX, i.e. an activation of the innate immune 
system [15], and the direct toxicity of PTX on the sensory and motor neurons [2, 
16-22]. Mitochondrial dynamics have recently arisen as a topic of interest for the 
uncovering of the mechanisms of CIPN and more specific, that of PIPN [2].  
A great degree of correlation has been observed between mitochondrial 
dysregulation and the neurodegenerative phenotypes of the nervous system, both 
central and peripheral. The loss of function of any of the mitochondrial elements - 
the electron transport chain, transmembrane potential or mitochondrial DNA 
(mtDNA) integrity – could lead to some form of peripheral neuropathy. The 




especially important for proper neuronal function. The dynamic environment with 
varying Ca2+ concentrations or ATP demand are the main factors regulating 
mitochondrial trafficking along the axon [23]. The loss or alteration of 
mitochondrial dynamics and axonal mitochondria replenishment mechanisms 
might be involved with many neurodegenerative diseases [2, 3, 5, 22, 24-29]. 
CIPN symptoms range from paraesthesia to sharp stinging pain sensations in the 
lower distal extremities, suggesting its retrograde modality. Wilkes et al. [30] and 
Gutierrez-Gutierrez et al. [31] have demonstrated that the longer nerves are more 
susceptible to neurodegenerative damage than the shorter nerves. This length-
dependent characteristic is likely related to the higher energy requirements by much 
longer nerves [32, 33]. In healthy neurons, this energy is provided by mitochondria, 
therefore, mitochondrial dynamics emerge as a with a significant role and 
pathological alterations of such, are strong indicators of neurodegenerative disease 
progression [3, 5, 16, 34]. The mitochondrial network also emerges as a potential 
target for treatment strategies. However, few studies have explored if mitochondrial 
influx can provide neuroprotection, for example, against CIPN. 
In this study, it was investigated if the neuroprotective mechanism of Fluocinolone 
Acetonide (FA), a steroid recently shown to mitigate PTX-induced 
neurodegeneration in vitro and PIPN in vivo, confers its neuroprotection through 
its effect on mitochondrial dynamics. A novel dual mitochondrial staining 




This tool broadens the understanding of the mitochondrial role in PIPN as well as 







1. The significance of mitochondria to neurons 
 
The function of neurons in the body is an energetically costly affair [23]. While 
occupying significantly less than 20% of the body’s mass, it consumes almost 
20% of the body’s resting energy metabolism [35]. The high-energy 
consumption of the nervous system is mostly devoted to the maintenance of the 
resting membrane potential. This is required for the transmission of action 
potentials which depolarises the membrane, requiring the continual transfer of 
the ions against the concentration gradient to maintain the resting potential 
across the membrane [36]. Therein lies the heavy dependence of neurons on 
mitochondria for its energy metabolism requirements. Therefore, any 
dysfunction of the mitochondria especially those stemming from mutations of 
mitochondrial DNA (mtDNA) can often be linked to muscle or neuronal 
disorders due to the heavy dependence on energy metabolism these cell types 
have [37, 38]. This is a problem further made apparent as seen in the higher 
occurrence of neuronal-related birth defects in offspring from females of 
advanced ages, especially in consideration of the fact that mitochondria and the 
associated mitochondrial genetic code are similarly maternally transmitted [39]. 
A quick glance through the list of neurodegenerative disorders, reveals that a 
great number of diseases of the central nervous system (CNS) to those of the 




Therefore, it would be highly plausible that neuropathy associated with 
chemotherapy would stem from some form of mitochondrial dysfunction.  
Mitochondria are essential to all cells in the human body and perform many 
functions in these cells as well as performing additional specialised roles in 
neurons, making them much more critical especially to the function of neurons. 
Mitochondria play a role in a number of signalling pathways in the cell e.g. 
regulate the intracellular mitochondrial reactive oxidative species (mtROS) 
levels in the cell [41]. The intracellular concentration of mtROS is tightly 
regulated and is capable of inducing a number of pathways via concentration-
dependent activation of a number of cellular mechanisms. These cellular 
mechanisms range from hypoxia defensive mechanisms, abrogation of 
neuroinflammatory responses or the commitment of the cell towards cell death 
[41]. 
Furthermore, the specific roles of mitochondria in neurons are mainly centred 
about two main functions, the location-dependent Adenosine triphosphate 
(ATP) production and Calcium ion (Ca2+) buffering homeostatic requirements. 
These two functions of mitochondria are quintessential towards the 
maintenance of neuronal health as shown in Figure 1, with the mitochondria 
serving as mobile homeostatic regulators of the axoplasm. It is well known that 
mitochondria are not individual organelles displaying stochastic behaviour 




form interconnected networks with each other and have strong biochemical 
relationships with many other cellular components, especially in neurons [42]. 
However, these functions are an integral part of many biochemical pathways in 
the neuron and the mitochondrial health is also rejuvenated and tightly regulated 
by each other as well as by the host cell [43]. Mitochondria undergo fusion and 
Figure 1: A) Normal mitochondrial function in the neuron, carrying out Ca2+ 
buffering and ATP synthesis, required for normal neuronal function, trafficking 
in the anterograde direction along the axon to fulfil homeostatic requirements 
by Kinesin protein motors, with the aid of MIRO and milton (TRAK1/2). Adapted 
with modifications from [174]. B) Mitochondrial maintenance life-cycle, 
showing the mitochondrial network as a dynamic interconnected network which 
undergoes fusion and then fission as attempts to restore the health of the 
mitochondrial network, before undergoing autophagy after depolarisation and 
OPA1 activity is abrogated. Should restorative mechanisms succeed, the 
mitochondria would proceed in its solitary period where it would continue 
performing its location-dependent homeostatic function of ATP synthesis and 




fission to regulate the state of health of the mitochondrial network, also as part 
of a cycle as seen in Figure 1. Individual units of mitochondria undergo 
autophagy as necessary if repair mechanisms are insufficient in mitigating the 
damage to the remaining mitochondrial population. 
Mitochondria fusion is an important physiological function required for the 
maintenance of mitochondria health, which is important in the homogenizing 
of the contents of mitochondria. It is a rescue mechanism for healthy 
mitochondria to mitigate the damage present in dysfunctional mitochondria. 
This allows for protein complementation as well as facilitation of mtDNA repair 
mechanisms [28], thereby regulating the number of mtDNA nucleoids [44]. 
This arises as a response mechanism to damaged mtDNA. Mitochondrial fusion 
is facilitated with the aid of several transmembrane proteins found on the inner 
and outer mitochondrial membrane, mfn1 and mfn2 with the aid of OPA1. A 
loss of function in either would lead to neurodegenerative diseases, such as 
Charcot-Marie-Tooth disease type 2A by Mfn2 or Dominant Optic Atrophy by 
OPA1 [28]. Therefore, mitochondrial fusion activity is a key regulator of 
mitochondrial health and is key to the state of neuronal health.  
Mitochondrial fusion involves the co-ordinated fusion of four membranes, two 
inner and outer membranes of the two approaching mitochondria. With GTPase 
proteins mitofusins 1 and 2 anchored on the outer mitochondrial membranes 




them together to initiate the membrane fusion via folding of the linker attached 
to the GTPase domain. The membranes are brought closer together in order to 
facilitate fusion of the outer mitochondrial membrane [47], with parallels drawn 
to a process facilitated by bacterial dynamin-like protein (BDLP) with a similar 
structural organisation leading to membrane fusion [48]. The fusion of the 
mitochondrial inner membrane is facilitated by two protein isoforms of OPA1, 
one long and one short [49], working in tandem, requiring proteolytic cleavage 
by YME1L and OMA1, which are i-AAA transmembrane mitochondrial 
proteases [50, 51]. This is a process which is required as continued OPA1 
activity would maintain tubular mitochondrial morphology which would in 
turn, inhibit fusion of the inner mitochondrial membrane [52, 53]. However, 
this is a process which is found to be upregulated in the presence of increased 
levels of mtROS [54, 55], a strong indicator that mitochondrial fusion is a 
compensatory mechanism by mitochondria to cope with heightened levels of 
mtROS. Therefore, it can be said that mitochondrial fusion is a necessary 
process to mitigate the damage to other cellular components as well as to reduce 
the damage to the remainder of the mitochondrial population.  
However, if mtROS accumulates sufficiently, permanent membrane 
depolarisation would occur with prolonged openings of mitochondrial 
membrane transition pore (MPTP). As a result, mitochondrial fusion would no 
longer be possible, as the inner membrane potential is required for 




mitochondria with a functional mitochondrial transmembrane potential, the 
fusion event will not occur [58]. Instead, they would increase the likelihood of 
fusion of the dysfunctional mitochondria with lysosomes to form 
autophagosomes [58-61] in order to maintain a homogenous healthy population 
of mitochondria in the cell as shown in Figure 1. 
Mitochondrial fission is a process involving an elongated mitochondrion 
undergoing equal or unequal division of organelle components into two discrete 
shorter daughter mitochondria. It is also used as a means of segregation of 
irreversibly damaged portions of the mitochondrion. This is a process which 
occurs instead, in mitochondria with permanent inner membrane depolarisation, 
allowing for the damaged daughter mitochondrion to be sequestered and 
degraded via autophagy [62]. This is a process primarily mediated by Dynamin-
related protein 1 (DRP1) via tight controls on the dynein function in neurons 
[63]. It is a process which serves dual functions in the protection via a 
segregation method as well as a method of self-renewal of the mitochondrial 
population in the cell. As mitochondria are very important to neuronal function, 
the state of health of the mitochondria population in the neuron would also 
correlate strongly with the health of the neuron. 
The mitochondria in a cell exists as a network which regulates itself, seeking to 
homogenise the composition of the mitochondria in its efforts to mitigate the 




removal of damaged mitochondria via autophagy. This is a process which 
occurs in a cycle of fusion and fission in the mitochondrial population, with 
fission as the autophagy checkpoint [61]. The damaged mitochondria are first 
prioritised to undergo mitochondrial fusion for matrix homogenisation, before 
undergoing fission to sequester the damaged components if the damage is 
unable to be repaired. For example, if a mitochondrion undergoes 
depolarisation, it will either invoke repair mechanisms to restore membrane 
potential and in failing so, will induce autophagy of the damaged mitochondria 
as displayed in Figure 1 [61]. This would suggest that the rate of mitochondrial 
fission is indicative of the efficacy of the mitochondrial quality control 
mechanisms, with mitochondrial fusion being inhibited in the events of 
mitochondria with extensive damage, e.g. with a depolarised inner membrane. 
Therefore, in situations of extensive stress to the mitochondria, the ratio of 
mitochondria fission to mitochondrial fusion might be key towards the 
understanding of the general health of the mitochondrial population in the cell. 
Therefore, this not a property which is easily studied due to the low probability 
of occurrence in the cell, requiring extensive periods of imaging of the 
mitochondria, which would induce phototoxicity-associated mitochondrial 
damage. Therefore, there exists a need for a method to determine the rate of 
fusion in a manner without direct observation of the event to reduce 




One feature of the mitochondria exclusive to the neurons, is the mitochondrial 
translocation along the axon. While most cells measure in the micrometres, 
neurons can exist from the micrometre scale to the centimetre scale due to the 
presence of specialised cellular projections: the axons. Therefore, it poses an 
extreme situation for the energy debt and distribution of mitochondria in 
neurons, especially towards the distal ends of the axon. This would in turn, 
make neurons more susceptible to degeneration from any axonal mitochondrial 
dysfunction in a length-dependent fashion. Mitochondria are not just the sites 
of ATP synthesis or Ca2+ buffering along the axon, but rather, they maintain the 
homeostatic levels of ATP and Ca2+ in the axoplasm by monitoring the transient 
levels of ADP [33] and Ca2+ ions along the axon [64]. These homeostatic 
mechanisms might work in tandem with mitochondrial tethering as well as 
adaptor proteins to the transport proteins, dynein and kinesin. These processes 
work in collaboration to ensure the mitochondria are mobilised to locations with 
high energy demand, such as the nodes of Ranvier and the growth cones [65] 
with the aid of microtubule anchors such as syntaphilin [66]. The second 
primary function of the mitochondria is paramount towards the maintenance of 
cytoplasmic Ca2+ concentrations; moving the mitochondria towards locations 
with transient spikes in Ca2+ concentrations for homeostatic regulation. Each 
function of the two essential functions of the mitochondria are driven by 




the mitochondrial population especially important to the functions of the neuron 
in the axon. 
The homeostatic-dependent regulation of mitochondrial mobility is based on 
the interaction between the adaptor proteins, the mitochondria as well as the 
motor proteins themselves. Microtubules stretch along the axon in long 
continuous fibres and are protected from their dynamic instability via 
attachment of tau proteins [67, 68]  and are the main highways for long distance 
transport of axonal cargo and mitochondria [69]. Therefore, the motor proteins 
primarily responsible for anterograde or retrograde trafficking of mitochondria 
are kinesin and dynein. The mechanisms controlling the trafficking are 
mediated by the adaptor proteins from the Kinesin superfamily (KIF) such as 
mitochondrial Rho GTPase 1 (MIRO1), milton, trafficking kinesin-binding 
protein 1 (TRAK1) or fasciculation and elongation protein-ζ1 (FEZ1) [62], 
depending on the genetic regulation from upstream cellular triggers. As the 
microtubules are orientated in a singular fashion in the axons of neurons in the 
peripheral nervous system, with the plus (+)-ended pole orientated towards the 
distal end while the minus (-)-ended pole orientated towards the proximal 
direction. The directionality of the polymerisation of these monomers would 
then determine the respective anterograde and retrograde trafficking of 
mitochondria by kinesin and dynein motor proteins. However, due to the 
attachment of both kinesin and dynein motor proteins onto the mitochondria at 




direction of the mitochondrial transport than the motor proteins alone, resulting 
in the haphazard bidirectional transport of mitochondria observed in some 
situations. This ‘tug-of-war’ between the opposing kinesin and dynein motors 
is key towards the eventual determination of the ultimate direction of 
mitochondrial transport. 
The activity of these adaptor proteins in the determination of mitochondrial 
trafficking behaviour might be dependent on immediate Ca2+ axoplasmic 
concentrations. There are several hypotheses about the mechanisms towards the 
methods of regulation the adaptor proteins has with the Ca2+ concentrations and 
the motor proteins. However, the one fact which resounds throughout all the 
hypotheses would be the halting of mitochondrial movement in regions of high 
Ca2+ concentrations. Whether it is a combination of the detachment of the motor 
proteins from the microtubules or the anchoring onto actin filaments with the 
aid of Myosin V, or a mutually exclusive case, the exact biochemical pathway 
regulating this process has not been established. This is a pathway stemming 
from the observation of mitochondria at synaptic terminals [36, 70], wherein 
ATP synthesis and Ca2+ buffering is required [71, 72]. The loss of which would 
abrogate synaptic transmission completely [73, 74]. Therefore, it can be said 
that Ca2+ levels within the axon is needs to be a tightly regulated homeostatic 
process by the mitochondria, and failure of which would lead to damage to the 




2. Mitochondria dysregulation arising from PTX-induced peripheral 
neuropathy 
 
PTX is a drug which is commonly used in several common chemotherapy 
regimens, especially targeted at breast, ovarian, prostate, ovarian, esophageal 
and non-small cell lung cancers [75]. This is facilitated via PTX binding to α 
and β tubulin subunits, blocking the GTPase activity, thereby stabilising the 
unstable structure of the microtubules and also enhancing the polymerisation of 
the microtubules. This process facilitates the strengthening of the M-loop of β-
tubulin binding to adjacent tubulin subunits [76]. This in turn, would lead to the 
effective arresting and subsequent killing of the cancer cells during M-phase, 
due to the inactivation of the dynamic instability-based depolymerisation 
activity of the microtubules during anaphase [77]. However, due to the systemic 
nature of PTX chemotherapy treatment, many other parts of the body are 
exposed to the PTX through systemic circulation, inclusive of the neurons of 
the peripheral nervous system which are one of the most severely affected. The 
symptoms of PTX-induced peripheral neuropathy (PIPN) begin with 
paraesthesia and moderate to severe pain in the upper and lower extremities in 
a stocking-and-glove distribution as shown in Figure 2, which can progress to 
muscle weakness and cramps if left unattended to. However, especially with 




the motor neurons, leading to the subsequent muscle weakness symptoms after 
sensory nerve degeneration [6, 78, 79]. Physiological symptoms include 
retrograde axonal degeneration, secondary demyelination and in severe cases, 
loss of nerve fibres [78]. The progression of PIPN has also been found to be 
correlated with a length-dependent axon degeneration, wherein neurons with 
longer axons are more susceptible to neurodegeneration [80]. This is a trend 
which could potentially have implications towards the disease progression 
mechanisms, which could elucidate a candidate for rescue mechanisms. There 
are several proposed neurodegenerative pathologies available in the literature 
and while each has its own merit in their contribution towards PIPN, each 
hypothesis might serve as its own contributing factor culminating in the 
Figure 2: Paclitaxel (PTX) toxicity on dorsal root ganglion neurons, has a 
stocking-and-glove distribution. PTX changes orientation of microtubules, 
disrupting axonal transport, and induces uncontrolled Ca2+ release from 
axoplasmic reticulum, leading to retrograde neurodegeneration.   Adapted 




eventual phenotypic response in the form of neuropathy. Especially in 
consideration of the in vivo environment, the effect of a systemic response to 
the drug cannot be underestimated, and it is important to consider the 
contributing effects of each proposed pathway to neuropathy.  
The first hypothesis stems from the well-known effect PTX has on tubulin, to 
stabilize the polymerisation of microtubules. Along which, the long-distance 
transport of axonal cargo such as mitochondria and synaptic vesicles are 
induced with the aid of kinesins and dyneins. Furthermore, neurons are 
comparatively enriched in stable microtubules than any other type of cell, along 
the axon of the neuron cell. Thus, the enhanced stability results in inhibition of 
the innate dynamic stability of the microtubules, resulting in unhealthy 
microtubule growth in the axon. Parallels to this version of neuropathy can be 
made with a form of Charcot-Marie-Tooth type 2 disease, which is a 
neurodegenerative disease arising from increased stabilisation of tubulin by 
heat shock factor binding protein 1 (HSBP1) due to a mutation. This would in 
turn, hinder axonal cargo transport, leading to a similar neurodegenerative 
phenotype as observed in PIPN from dysregulation of axonal transport, lending 
credence to the effect which enhanced stability of tubulin has on the 
neurodegenerative effect [80]. The theory further explains the lack of effect on 
the central nervous system (CNS) due to the inability of PTX to cross the Blood-
brain barrier (BBB), but when directly introduced into the cerebral cortex, 




82]. PTX has also been found to be neuroprotective at low doses of about 1 nM, 
but promotes neurodegeneration at a higher dose of any above 50 nM [83]. PTX 
has a similar binding site as tau protein, a naturally occurring microtubule 
stabilising protein albeit with a higher binding affinity [84, 85]. As a result, 
PTX would prevent the dynamic microtubule remodelling processes occurring 
via the detachment of tau proteins through competitive binding processes with 
tubulin subunits [86]. 
An alternative look on the downstream effects of microtubule stabilization, 
focuses on the alterations to axonal transport. However, in consideration of the 
composition of the microtubule gliding assay, wherein PTX is used to stabilise 
the polymerisation of the tubulin subunits, it has been established that there 
would not be an effect on the transport mechanisms itself [87], suggesting that 
the effect which PTX has on motor protein/microtubule interactions is not from 
a physical block of the motor protein activity. Furthermore, it is established that 
the binding site of either tau proteins or PTX lies on the inner surface of the 
microtubules and likely does not interfere with the microtubule associated 
proteins (MAP), such as the motor proteins, interaction with the microtubules 
[18]. However, it is worth considering that the study model was an in vitro study 
which cultured the condition for a duration of a few hours, which might not be 
comparable to the longer-term incubation as present in chemotherapy patients 
of an exposure of up to a day or longer. A possible explanation for the long-




mollusc which shares 96% of the primary structure sequence of the tubulin 
protein [88]. This study showed an accumulation of microtubule filaments of 
different polarities at axonal swellings, which might have a drastic implication 
in alterations of the mechanisms regulating the direction of axonal transport 
[83]. Threrefore, contributing towards the neurodegeneration from negatively 
affecting the mitochondrial supply to the distal axons, regions which might 
require additional Ca2+ buffering [75]. This is a thread of investigation which 
was eventually confirmed as a phenomenon in neurons as an early event, but 
not primary to the causation of neurodegeneration, but it would exacerbate the 
neurodegenerative mechanisms [89]. 
An alternative approach to uncover the disease progression mechanisms 
includes a more systemic response to the chemotherapy insult which involves 
the inflammatory pathways, from the robust activation of the astrocytes [90, 91] 
and microglia [92] in the spinal cord. The microglia contribute to hyperalgesia 
via the release of tumour necrosis factor alpha (TNF-α) [93] from binding and 
activation of Toll-like receptor 4 (TLR4) by PTX [94], which was shown to 
upregulate the expression of transient receptor potential cation channel, 
subfamily A, member 1 (TRPA1), and transient receptor potential cation 
channel vanilloid 4 (TRPV4) in nociceptors. These two proteins are crucial to 
the activation of neuroinflammatory hyperalgesia pathways [95]. The 
astrocytes found at the spinal also release proinflammatory cytokines, which 




processes of sphingosine-1-phosphate receptor 1 (S1PR) [90, 96]. Furthermore, 
the onset of PIPN further triggers infiltration of macrophages towards the 
sensory nerves, thereby leading to proliferation of Langerhans cells at the distal 
ends of the nerves at the epidermal layer [92, 97, 98]. This series of events 
would contribute towards an acute sharp pain in the initial days followed by a 
dulled chronic pain as a result of PIPN. Upon reaching the chronic stage, it has 
been shown that the hyperalgaesic pain may persist despite stoppage of PTX 
treatment. This phenomenon at the distal end of the DRG nerves might be the 
contributing factor towards the retrograde fashion of demyelination of the 
nociceptive nerves from the activated neuroinflammatory pathways [99]. 
Another approach to the neuroinflammatory-based PIPN pathology is based 
upon the upregulation of monocyte chemoattractant protein-1 (MCP-1) in 
DRGs. This would be a part of the neuroinflammatory pathway contributing to 
hyperalgesia, thereby increasing the excitability of the nociceptors by 
recruitment of monocytes, activated T cells and dendritic cells [100], which 
have been found to increase intracellular Ca2+ levels directly [101].  A study 
which abrogated the signalling pathway of MCP-1 significantly reduced the 
associated pain symptoms [15, 101], which also reduced the neuroinflammatory 
effects of macrophage recruitment and subsequent Langerhans cells recruitment 
at the epidermal layer. The same study also introduced a macrophage toxin, 
Clodronate, and found that the hyperalgesia symptoms were eliminated in rats 




use of a drug, Minocycline, further supports the key role which macrophages 
play in the onset of neuropathic pain [98]. Collectively, these studies have 
shown that the neuropathic pain pathways contribute towards 
neurodegeneration, but are working independently of the other mechanisms 
leading towards the ultimate neurodegeneration of the neuron, as 
neurodegeneration is not completely absent in their respective rescue 
mechanisms to abrogate neuroinflammatory pathways alone. 
The next hypothesis towards PIPN is heavily centred on mitochondrial 
dysfunction. It was found that PTX treatment would lead to mitochondrial 
dysfunction, which strongly contributes towards the propagation of 
neurodegeneration. The mitochondrial function in the neurons are especially 
critical to neuronal function and survival. Therefore, the following hypotheses 
explaining the pathology of mitochondrial dysfunction aim to describe the 
subsequent disease mechanisms leading into PIPN. An important distinction 
between the neuroinflammatory hypotheses and the mitochondrial dysfunction 
hypotheses lie in the experimental outcomes. In the in vivo neuroinflammatory 
studies, the pain levels of the animals were the primary experimental output, 
while in the mitochondria-based studies, the primary experimental outcome for 
in vivo-based studies lie in nerve fiber cross-sectional area, a more accurate 
reflection of the state of neurodegeneration. There has been an increase in 
popularity of studies of mitochondrial dynamics to determine the pathological 




of CIPN are limited severely in the types of experimental outputs available to 
the researchers, primarily centred about pain levels and skin biopsies which 
contain intraepidermal nerve fibre (IENF) densities in select studies [102]. The 
study of IENFs would serve as a minimally invasive method of determination 
of nerve fibre densities of nerves of different myelinated states, depending on 
the location of the biopsy [103]. 
In 2006, there was a study which revealed a novel binding partner to PTX, 
neuron calcium sensor-1 (NCS-1), leading to the oscillations of intra-
axoplasmic Ca2+ levels which was found to be independent of mitochondrial 
and exoplasmic Ca2+. Rather, the spikes in the axonal Ca2+ levels were due to 
the binding of NCS-1 to Inositol 1,4,5-triphosphate receptor (IP3R), inducing 
an initial release of Ca2+ ions from the axoplasmic reticulum. Therefore, the 
ion-gated receptor Ryanodine Receptor (RyR) would open, culminating in a 
continual oscillatory Ca2+ induced Ca2+ release (CICR) behaviour [104, 105]. 
In fact, this PTX-induced mechanism is corroborated in a similar study done on 
CNS neurons found in the spine on a rat model, wherein a gain-of-function 
knock-in mutation for decreasing affinity to Ca2+ ions, thereby decreasing the 
axoplasm Ca2+ threshold for CICR through the RyR channel from the 
axoplasmic reticulum was sufficient to significantly attenuate the 
neurodegenerative effect of PIPN [106]. Following Ca2+ oscillatory release 
from the axoplasmic reticulum, the Ca2+ signalling pathways dependent on the 




completely abrogated. Furthermore, the Ca2+ activated protease Calpain, which 
has been found to cleave NCS-1 in PTX-induced CICR, would effectively 
remove the trigger to induce controlled Ca2+ release from the axoplasmic 
reticulum [107, 108]. This effect is compounded in consideration of the altered 
microtubule dynamics from PTX treatment, as the replenishment of the proteins 
found in the axon is delivered to the axoplasmic reticulum for translation by 
delivery of mRNA from the nucleus via axonal vesicles [19]. As the Ca2+ 
signalling pathways have effectively been abrogated within the first 6 hours of 
PTX exposure [108], mitochondria trafficking would subsequently also cease 
to function effectively, halting the trafficking of any healthy mitochondria from 
the soma. However, from the initial spikes in the oscillatory Ca2+ levels in the 
axoplasm, the mitochondria are trafficked to areas with high Ca2+ 
concentrations to take in the sudden spike in Ca2+ in the axoplasm. As a result, 
it would propagate a spike of Ca2+ levels within the mitochondrial matrix, until 
the buffering capacity of the mitochondria is exceeded. There would then be a 
resulting excess of mtROS produced, from the increased activity of the electron 
transport chain on the inner mitochondrial membrane (IMM) [109] from the 
excess Ca2+ levels. This is facilitated by the increase in Na+ in the mitochondrial 
matrix by the Na+/Ca2+ antiporter protein, while the Na+/H+ antiporter protein 
accumulates H+ ions in the matrix for transport into the intermembrane space 
by complexes I, II and III of the ETC, thereby increasing the rate of mtROS 




uncontrollably, the mPTP opens, depolarising the mitochondria irreversibly 
[109-112]. A study successfully managed to halt the mitochondrial 
degeneration process via the inhibition of Complexes I and III of the ETC, via 
the prevention of excess mtROS production, thereby halting the subsequent 
neurodegenerative mechanisms from mitochondrial dysfunction [16]. This is 
indicative of the crucial role which mtROS accumulation has towards the 
neurodegeneration processes. Another study went further upstream of the 
degeneration mechanism process tree and attempted to block the initial release 
of Ca2+ by inhibition of IP3R and RyR, which also successfully managed to 
prevent the mitochondrial dysfunction and subsequent neurodegeneration 
[113]. This is strongly supportive of the Ca2+ induced mitochondrial 
dysfunction model towards neurodegeneration.  
Furthermore, following membrane depolarisation of the mitochondria in the 
axon, there would be a dysregulation of mitochondria dynamics in the axon due 
to two factors. The first arising from the loss of membrane potential-dependent 
mitochondrial fusion for mitochondria rescue from the proximal mitochondria 
(PM), secondly, the altered microtubule dynamics from the mixed tubulin fibre 
polarities will lead to altered mitochondria dynamics resulting in a loss of ATP 
production from the depolarised mitochondria. These depolarised mitochondria 
possess a vacuolised and swelled phenotype [2, 3]. As the mitochondria 
undergoes membrane depolarisation with the opening of the mPTP, the released 




processes via degradation of the neurofilaments. A study done in 2004 also 
further confirmed the PIPN diseased state progression via inhibition of calpain 
proteases, which was sufficient to rescue the neurons and subsequent 
prevention of the neurodegenerative processes [114]. 
The full in vivo systemic response would be inclusive of all the mentioned 
mechanisms working collectively towards neurodegeneration and the causation 
of the neuropathic pain. However, it would be important to note that the causes 
of the neurodegenerative mechanisms and neuropathic pain, though initiated 
from the same drug, undergo very different mechanisms to present itself as the 







Table 1: Neuropathic Mechanisms arising from PTX 




1. Loss of axonal transport 
2. Disruption of microtubule dynamic 
remodelling processes 
3. Loss of somatic control through axonal 
vesicles 





Neuroinflammation 1. Induced by TLR4 activation sends 
macrophages to the sensory nerves 
2. Proliferation of Langerhans cells at 
distal tips lead to acute pain 
3. Hyperalgesia induced by inflammation 
increase sensitivity to pain as well as 
retrograde demyelination of nociceptors 
4. Acute pain phase is proceeded by 
chronic dulled pain persisting beyond 
stoppage of chemotherapy treatment 





1. NCS-1 binding by PTX induced CICR, 
Ca2+ released into axoplasm in 
oscillatory behaviour from axoplasmic 
reticulum 
2. Axonal mitochondria are trafficked to 
sites of high Ca2+ concentration to buffer 
Ca2+ concentrations 
3. Trafficked mitochondria accumulates 
mtROS from Ca2+ overload, leading to 






1. Ca2+ release induced via 
neuroinflammatory pathways 
exacerbates CICR phenomenon in 
axoplasm. 
2. Microtubule hyper-polymerisation 
disrupts directional control of axonal 
transport, abrogating rescue mechanisms 
from soma 







3. Neuroprotection in DRGs with FA corticosteroid treatment  
 
Despite the many pathways to neurodegeneration and neuropathic pain, the 
methods toward which many researchers approach PIPN have been singular, often 
tackling the problems as individuals rather than systemic-oriented approaches. 
Therefore, looking at the various pathways leading towards PIPN, a study which 
was published in 2016 did a drug screening of 2322 compounds in order to identify 
a neuroprotective drug especially towards PIPN [115]. Through this study which 
did both an in vitro ATP assay of neuronal function [116, 117, 118] as well as an 
in vivo IENF density degeneration test [119], it can be concluded that FA has a 
functional role in the reduction of neurodegeneration which also reduced the pain 
levels experienced by the rat as evidenced by a restored thermal withdrawal latency 
back to the wild-type response [115]. FA is a hydrocortisone derivative which has 
been commercially available since the 1960s for use in treatment of psoriasis as a 
topical steroid [120, 121], having since been used in a wider range of 
dermatological applications as an anti-inflammatory drug. Furthermore, it has also 
been repurposed for use as a topical intravitreal implant in the prevention of diabetic 
macular edema [122-125], therefore, it might be significantly easier and promising 
as a drug to be approved by the relevant health authorities for use in the mitigation 
of PIPN.  
FA belongs to the fourth class of a USA classification of corticosteroid potency, a 




to reduce dermatological inflammations [126, 127]. It is also well known of the 
cross-reactivity of the lipophilic hormones with a similar group of functions, such 
as cortisone, progesterone, androgens or oestrogen [128]. Furthermore, FA, being 
a hydrocortisone derivative, has similar binding sites as hydrocortisone which has 
been originally thought to bind to mineralocorticoid receptors [129] and 
glucocorticoid receptors (GRs) [130] exclusively, has been revealed to also bind to 
progesterone receptors [131, 132] just as progesterone is able to bind to GRs [133, 
134]. However, the differences lie in the binding affinity between the respective 
hormones and the associated receptor, indicative of positive feedback regulatory 
mechanisms the hormone levels found in the blood has on regulating distant cellular 
targets. For example, the binding affinity of cortisone and the mineralocorticoid 
receptor is ten-fold that with the GRs, indicative of an activation of GR -mediated 
mechanisms only when levels of hydrocortisone exceed a certain concentration in 
the blood  [135, 136]. The effects of corticosteroid binding mechanisms are 
numerous and a relatively recent discovery of the neuroprotective behaviour of the 
progesterone receptor [137] can be key towards the understanding of the 
mechanisms which FA-ligand binding lead towards neuroprotection [138]. The 
effect of neuroendocrinology-related research towards the development of 
therapeutics is still a budding field wherein not much has been elucidated about the 
exact mechanisms of neuroprotection. However, progesterone has been tested in 
treatments of neuropathic pain [139], as well as associated allodynia [140], and is 




treatment [139], showing parallels in the prevention of neuropathic pain in the rat 
as was done by FA in a study done by Centinya-Fisgin et al., an in vivo study model 
of prevention of PIPN [115]. Progesterone has also been shown to reduce the 
progression of neuroinflammation in a repeated CNS trauma rat model [141]. With 
another study proving that a progesterone receptor agonist is able to mitigate the 
expression of proinflammatory mediators, TNF-α and iNOS, in a model of motor 
neuropathy [142], which coincide with the PTX-induced TNF-α-initiated 
neuroinflammatory pathways [93]. Therefore, although not yet proven, it might be 
possible to hypothesize the mitigation of neuropathic pain of PIPN through 
abrogation of neuroinflammatory mechanisms with FA-Progesterone receptor 
interactions.  
Furthermore, it is noteworthy that despite the normally understood hormone 
receptors, there are other binding sites found on the mitochondria as well, with 
similarity to the nuclear glucocorticoid response elements (GREs) [143]. The GR 
has many cellular targets, but of great interest to neurodegenerative mechanisms is 
the role it plays in mitochondria upon mitochondria localisation [144, 145]. 
However, it was revealed that it the mitochondria had polarising responses to low 
and high doses of corticosteroids [146]. The function of glucocorticoid receptors is 
mediated via translocation into the mitochondria with the aid of the complex 
formed by heat shock protein 70 (HSP70) and heat shock protein 90 (HSP90) with 
a Bcl-2 associated athanogene (Bag-1) [147, 148]. It was then found that in low-




apoptotic precursor proteins such as cytochrome C from mitochondrial release, 
which would prevent membrane permeabilisation by blocking mPTP formation in 
the outer mitochondrial membrane as well as enhancing Ca2+ storage capability 
[146]. Therefore, it would stand to support the observed attenuation of the PIPN 
phenotype with low dose FA treatment [115], through enhanced Bcl-2 function in 
response to low dose corticosteroid treatment. Furthermore, other forms of 
corticosteroid activity in the mitochondria through binding to other GREs on 
mitochondrial proteins include direct attenuation of complex I activity by 
suppressing electron donation from NADH to complex I [149], thereby halting the 
mtROS overload mechanisms initiated by Ca2+ overload in the mitochondria. This 
function of ETC inhibition is not abrogated in the presence of RU486, a known GR 
inhibitor, also known as mifepristone [150], which is indicative of mechanisms 
involving corticosteroids exclusive of the GR [151]. 
Furthermore, through the PIPN mechanisms earlier highlighted, the CICR induced 
Ca2+ overload in the axoplasm would be a similar effect in glutamate-induced 
excitotoxicity has been found to be attenuated in low dose corticosteroid treatment 
[152]. It was found that in the activation of plasmalemmal Ca2+ ATPase by 
glucocorticoids, it was possible to lower the intracellular concentration of Ca2+ 
levels below basal levels, mitigating the damage induced by sudden spikes in Ca2+ 




Therefore, from a top-down and subsequent bottom-up approach, from the drug 
screening phenotypic response, to identify FA as a neuroprotective drug to mitigate 
the neurodegenerative processes as well as the associated neuropathic pain, to the 
identification of how parallel studies have studied the effects of cortisone and its 
derivatives on the respective neurodegenerative and neuroinflammatory 
mechanisms, FA does seem to be especially useful in attenuating the effects of 
PIPN. However, the associated neuroprotection from FA is only present on acute 
and low doses of corticosteroids, as also seen from the phenotypical evidence of 
the loss of neuroprotective evidence from higher doses of FA on PIPN [115]. The 
impact these mechanisms would have on the mitochondria, would probably be the 
prevention of the mitochondrial depolarisation process, as well as associated 
mitochondrial dynamics would be the foci of this study. 
Table 2: Neuroprotection conferred by FA 
Phenomenon Pathology References 
Reduction of 
Neuropathic Pain 
1. Reduction of neuroinflammation via 
progesterone receptor binding 
2. Downregulation of proinflammatory 




1. Prevention of mitochondrial release of 
cytochrome C 
2. Prevention of mPTP translocation to 
outer mitochondrial membrane, 
mitigating depolarisation of 
mitochondria  
3. Reduction of Ca2+ accumulation in 
axoplasm by plasmalemmal Ca2+ 
ATPase activation 
4. Mitigation of Ca2+ overload in 
mitochondria by preventing mtROS 







Materials and Methods 
 
1. Preparation of compartmentalised chamber system 
 
A master mold with individual compartmentalised chambers, of 12mm width with 
12 bundles of 10 microchannels of 10 µm width each spaced 35µm apart between 
bundles of microchannels, was prepared via a high resolution photolithographic 
process as detailed in [153] which was used for a soft lithographic molding process 
with Sylgard 184 polydimethylsiloxane (PDMS) (Dow Corning, Michigan) where 
PDMS monomers were mixed with the curing agent in a 10:1 ratio by weight with 
thorough mixing and poured onto the silicon master mold, before it is placed in a 
vacuum chamber for 20 minutes for air bubble removal and placed in an oven for 
2 hours at 70°C for curing. After curing, the PDMS is carefully removed from the 
master mold and individual segments are cut out of the PDMS block in quadruples 
and the wells are punched with the use of 6 mm dermal biopsy punch tools (Huot 
Instruments, Michigan). The punched PDMS blocks are pasted with Magic green 
tape (3M, Singapore) and removed to remove any residual PDMS particles before 
they are bonded onto 50mm diameter glass-bottomed dishes (Willco-dish®, 
Amsterdam) of #1.5 glass thickness cleaned with isopropanol with the aid of with 
50sccm of O2 and 70W of oxygen-based plasma treatment for 90 seconds (Cute-
MP, Femto Science, South Korea) of both the glass surfaces and the PDMS devices. 
After plasma bonding, the devices are sterilised with the use of Ultraviolet light 




and removal of possible air bubbles in the microchannels. The wells are then 
washed once with water and treated with 100x dilution of Poly-D-Lysine (PDL) 
(Sigma-aldrich, Darmstadt) in a 240x diluted solution of Laminin (Sigma-aldrich, 
Darmstadt) for 4 hours at 37°C in the incubator. After PDL/Laminin treatment, the 
wells are washed 3 times with 1x Phosphate buffered saline (PBS) (Thermo Fisher 
Scientific, Massachusetts) and 2 times with 18.2MΩ resistance deionised water 
(NANOpure, Thermo Fisher Scientific, Massachusetts). 
2. DRG extraction and culture 
 
All experiments involving animals were conducted in accordance to protocols 
approved by the Institutional Animal Care and Use Committee (IACUC) of the 
National University of Singapore and by guidelines outlined by the National 
Advisory Committee for laboratory Animal Research (NACLAR) under the Agri-
Food and Veterinary Authority of Singapore. Unless mentioned otherwise, all 
tissue culture supplies were obtained from Life Technologies (Singapore). The 
dissection procedure was carried out on the 15th day of Embryogenesis. The 
pregnant Sprague Dawley rat was euthanised within the cage of housing via Carbon 
Dioxide (CO2) at a flow rate of 7.5L/minute for a duration of 10 minutes, until the 
rat stops breathing and signs of life can be determined to have ceased via pain 
response checks on the tail and change of bright red coloration in the corneal and 
pedal region to a dull pink. The site of incision is sterilised with 70% ethanol with 




muscle layers to expose the abdominal cavity. The uterus is then removed and 
detached from the cervix and ovaries, then placed within L-15 media with 1% P/S 
at 4°C. The embryo is subsequently removed from each respective amniotic sac and 
detachment of the umbilical cord. After which, the spinal column is exposed via a 
single incision along the temporal section of the cervical region of the embryo and 
the spinal cord is exposed via excision of the developing spinal column cartilage 
from cervical to sacral regions, then removing the spinal cord from the developing 
spinal column. The dorsal root ganglion (DRG) explants are then removed via 
individual plucking with a tweezer and placed into another dish of fresh 1 mL L-15 
media with 1%  Penicillin/Streptomycin (P/S) at 4°C with an equal volume of 
0.25% Trypsin by volume for 5 minutes at 37°C and quenched with 0.2 mL of FBS 
[154]. The cells are then resuspended in 50000 cells/5mL density and seeded near 
the microchannels in the wells for 5 minutes at 37°C for attachment, before 100µL 
of Neurobasal media with the addition of the following reagents with the respective 
dilution factors is added: 100x P/S, 100x Glutamax, 50x B27 supplement, 5000x 
glial derived Nerve Growth Factor (GDNF) and for elimination of non-neuronal 
glial cell contamination, 1000x 5-Fluoro-2’-deoxyuridine thymidylate synthase 
inhibitor (FUDR) (Sigma-Aldrich, Darmstadt) [155]. PTX was dissolved in 
Kolliphor EL/Ethanol 50/50 solvent by weight (Sigma-Aldrich, Darmstadt) at a 
stock concentration of 3.33mM and stored at -20°C. Fluocinolone Acetonide (FA) 
(Sigma-Aldrich, Darmstadt) was dissolved in DMSO solvent (Sigma-Aldrich, 




neuronal cell suspension was done at one side of the compartmentalised chamber 
system, and designated the soma chamber, with allowance of the axons to extend 
through the 10 µm wide microchannels to the chamber on the other side. For the 
first 4 days post explantation, the culture is left in the incubator at 5% CO2 at 37°C. 
50% of the media is then replaced with Neurobasal media every 3 days with the 
above mentioned media components until day 7, after which, only the same 
concentrations of B27 supplement is added with the Neurobasal media. 
3. Qualitative determination of axonal degeneration 
 
Drug optimisation experiments were necessary due to the hydrophobic porous 
nature of the PDMS compartmental device to absorb small hydrophobic molecules 
with great affinity. Therefore, experimental outputs were evaluated qualitatively 
for the biggest improvements in the axonal health of the neurons observed. 
Considerations for axonal health include the presence of blebbing and 
fragmentation of axons, disruptive processes which interrupt the smoothness of the 
axon, characteristic of neurodegenerative processes which proceeded in an 
intermodal fashion from the formation of blebs which eventually progressed to 
complete disintegration of the axon, progressing from the degeneration initiation at 
the blebs. 
4. Optimisation of MitoTracker dye concentrations 
 
Optimisation of MitoTracker concentrations was necessary due to the nature of the 




devices tend to take in hydrophobic molecules such as MitoTracker molecular 
probes, therefore, use of the working concentration as prescribed in other 
publications or literature would not have been as efficacious as for use in the 
experimental set up used in this study. DRG neurons were seeded at a density of 
50000 cells/well similar to intended experimental settings, with 4 concentrations of 
MitoTracker dissolved in respective proximal and distal media solutions, 200nM, 
300 nM, 400nM and 500 nM. The cells were incubated at 5% CO2, 37 °C and 95% 
humidity for 24 hours before imaging. Imaging parameters were optimised with the 
following considerations in mind, to reduce laser intensity with the best possible 
signal to noise ratio at 512 x 512, to maximise the temporal resolution of the time 
lapse video. Searching for ideal locations and suitable focus depth for imaging were 
conducted under 10% light intensity of the 110V halogen lamp with a red/green 
filter. Imaging parameters optimised from this process was subsequently used in 
the actual imaging experiment. 
 
5. Labelling of mitochondria and microscopy 
 
For drug treatments, the DRG cell culture would then be treated with the optimised 
concentrations of 200nM of PTX with/without 20nM FA in Neurobasal media with 
B27 supplement with antioxidants and 2X Glutamax and 400nM of MitoTracker 
Deep Red FM of the axonal chamber and 600 nM MitoTracker Orange CMTMRos 




change, effectively halving the media component concentrations. The microscope 
used is the LSM800 airy scan confocal system (Zeiss, Oberkochen) The 
microscopy configurations are set as follows with the use of Nikon 63x Fluorview 
oil-immersion lens at imaging speed 9 with 512 x 512 pixels resolution with laser 
intensity set at 0.2% for a 5mW red laser with 650V master gain and 49µm aperture 
size with 8 averaged frames giving a 5.03s temporal resolution per captured frame 
for dual photon imaging. Imaging modalities are as follows with 4 minutes of time 
lapse imaging after 24 hours, yielding a total of 49 frames per time lapse video. 5 
videos per treatment condition per device were taken on duplicate devices. 
6. Quantification of mitochondrial motility in DRGs 
 
The mitochondrial motility was measured via determination of mitochondrial 
velocity across different frames via a fixed temporal resolution of 5.03s between 
frames and 0.195µm/pixel for a 512 x 512 pixel resolution. Average velocities were 
quantified via summation of displacement of entire mitochondrial track and divided 
by the product of the temporal resolution of 5.03s and n-1 frames where n represents 
the number of frames wherein the mitochondria was tracked To quantify the 
mitochondrial velocity, images were analysed with the aid of the open source 
software Fiji and the movies obtained were aligned through the use of the 
‘StackReg’ and ‘TurboReg’ algorithm which was required to accommodate for any 
stage drift first, and denoised with the despeckle function in Fiji. The actual velocity 




mitochondria across the frames until the mitochondria disappears from view, stops 
moving or moves out of frame. The following parameters were obtained from the 
analysis from MTrackJ, average velocities of moving mitochondria, the ratio of 
directional movement as well as the ratio of static to motile mitochondria.  
Quantification of direction-specific mitochondrial trafficking was completed with 
the aid of comparison of progressive y-axis co-ordinates between tracking points, 
as the videos were always orientated in a down-up anterograde direction, resulting 
in a negative progressive y-value track being quantified as an anterograde direction 
mitochondria while a positive progressive y-value track being quantified as a 
retrograde direction mitochondria. 
Two anomalous situations which hindered tracking of motile mitochondria were as 
follows, ‘pauses’ and ‘set-backs’ being defined as intervals where the mitochondria 
moved less than 2 pixels (which arise due to ‘jittery’ conditions from manual 
tracking, wherein the ends of the mitochondria dimmed or resumed motion at the 
same position) and phases where mitochondria briefly appeared, disappeared and 
reappeared further along the axon in the same trajectory respectively.  
Analysis of mitochondria was done with two-dimensions despite the possibility of 
mitochondria travelling out of focus of the optical section of observation of the 
confocal microscope, making a three-dimensional approach able to accommodate 
for this shortcoming of a two-dimensional method. However, the observation of 




temporal resolution. Therefore, making a three-dimensional analysis not feasible 
which might result in severe under sampling of the fluorescence intensity to 
compensate for the temporal resolution. 
7. Quantification of ratio of PM vs DM 
 
The DM and PM would be dyed differently, with the proximal compartment dyed 
with 300nM MitoTracker Orange CMTMRos, while the axonal compartment 
would be dyed with 200nM MitoTracker Deep Red FM. This would allow for the 
tracking of the mitochondria from the soma into the axons. The total number of 
mitochondria labelled with only MitoTracker Orange and the total number of 
mitochondria labelled with both dyes would be determined automatically via Fiji’s 
‘Find Maxima’ function with a noise tolerance of 25, after denoising the video via 
the ‘Despeckle’ function. The number from one dye condition from each image 
would be compared against the total numbers of mitochondria found to obtain the 
proportion of DM to PM. The ratios from each treatment condition would be 
averaged to obtain the mean and statistical analysis would be done with the use of 
non-parametric Kruskal-Wallis with Dunn’s post hoc. P-values less than 0.05 were 
considered significant. 
8. Quantification of mobile mitochondria proportion 
 
The total number of mitochondria in the images taken at the axonal compartment 
images at the first frame of each time-lapse video is quantified via the ‘Find 




video is then converted to default 8-bit binary mode. The number of mitochondrial 
tracks is obtained with the aid of ‘Difference Tracker’ plugin in Fiji which has a 
comparative most accurate numbers of mitochondrial tracks with respect to other 
automated tracking methods [156]. The ‘DifferenceFilter’ function is used to obtain 
the reference differential video to track any moving mitochondria with the 
minimum difference filter = 12 and the difference frame offset = 2, while the ‘Mass 
Particle Tracker’ function was used to count the number of mobile tracks with the 
following parameters: Minimum tracked intensity = 20, minimum feature size = 2, 
initial flexibility = 25, subsequent flexibility = 40, min track length = 4. The output 
is taken from the total track counts as the total numbers of moving mitochondria. 
These parameters were optimised incrementally based on manual comparisons with 
observational corresponding with the following of moving mitochondria, to capture 





Results and Discussion 
 
1. MitoTracker dye and drug concentration optimisation 
 
Due to the hydrophobic nature of the material used in the soft lithography process, 
polydimethylsiloxane (PDMS), which is chosen for its ease of use in reproducing 
with high resolution microfluidic channels with the aid of a micropatterned silicon 
wafer. It is commonly known that PDMS absorbs a large amount of small 
molecules [157, 158]. This would have a progressive effect on the concentration of 
the molecules over time, especially in a 24-hour treatment window. Therefore, there 
is an imperative to conduct further optimisation of drug or molecular probe 
concentrations to reproduce the rescue effect which FA has on PTX treated axons 
as shown in the study conducted by Cetinkaya-Fisgin et al. which was not 
conducted on a similar PDMS device, but on a polystyrene 96-well plate [115]. 
This is especially important as the drugs or molecular probes used in this study are 
relatively hydrophobic in nature and would be susceptible to the absorptive effect 
which PDMS has on these small molecules.  
The eventual concentrations chosen for the final imaging experiment for 
mitochondria tracking were dependent upon qualitative decisions based on a 
number of factors. For the MitoTracker dye concentrations, the primary 
considerations were based on the minimum concentration which was required to 
produce clear distinguishable mitochondria shapes, with a maximum signal-to-




shapes of mitochondria to be obtained, as seen at 200 nM of MitoTracker in the 
axonal chamber in Figure 3. Also, in too high concentrations of MitoTracker, there 
would be indiscriminate labelling of other cellular structures, as seen at 500nM 
MitoTracker Deep Red in Figure 3, which would decrease the signal-to-noise ratio 
Figure 3: MitoTracker dyes concentration optimisation. Mitochondria were 
labelled with 200-500 nM of the mitotrackers. 200 nM MitoTracker Deep Red FM 
(purple, distal mitochondria) and 300 nM Mitotracker Orange CMTMRos (blue, 
proximal mitochondria) were found to be the optimal concentrations based on the 




as well, indicative of a parabolic relationship between the concentration and the 
signal-to-noise ratio obtained in the time lapse videos. Other considerations 
relevant towards the decision of the eventual concentration of MitoTracker chosen 
require sufficient labelling of mitochondria on the proximal side to produce a 
sufficiently clear and bright fluorescent signal of mitochondria crossing over from 
the soma with maximum signal-to-noise ratio, as seen in 300nM of MitoTracker 
Orange of Figure 3. 
For the PTX and FA concentrations, the primary considerations for the decisions 
for the choice of concentrations of FA and PTX used were from the biggest 
differences in axonal health from pure PTX treatment against the concentration of 
FA used in Figure 4. The concentrations used in the study conducted by Cetinkaya-
Fisgin et al. provided a good guide on the range of concentrations to be used for the 
optimisation experiment. Considerations of axonal health were based on the 
presence of blebbing or fragmentation of the axons found in the Calcein-labelled 
axons. There was an obvious trend of effect of neurodegeneration found in the pure 
PTX-treated neurons, with the presence of blebbing in a seemingly linear fashion 
on halving concentrations of PTX in the treatment medium. The rescue effect of 
FA on PTX-treated neurons was chosen qualitatively to determine the healthiest 
looking axons, with the biggest improved difference from the pure PTX treatment 
condition, as well as considerations of the choice of a concentration of PTX closer 
towards the clinically derived concentration of PTX used in chemotherapy 




guideline of chemotherapy regimens. Therefore, although the use of 200 nM of 
PTX might be less realistic, being on the extreme side of PTX concentrations, it 
was used as a contrast with several studies on PIPN which used 200 nM of PTX for 
their in vitro studies. However, 100 nM of PTX was used eventually with 10 nM of 
Figure 4: Drug concentration optimisation. DRG were exposed for 24 h to 0-200 nM 
paclitaxel (PTX) and 0-20 nM fluocinolone acetonide (FA) separately, and in co-
treatment. Axon morphology was visualised with Calcein AM and axon degeneration 
was assessed qualitatively. Chosen concentrations for treatment model was 100 nM 




FA with the greatest improvement in phenotypic outcome of axonal health, as seen 
in Figure 4, for use in the investigation into mitochondrial dynamics in the next 
phase of the study. 
 
2. Site-specific labelling of mitochondria to determine trafficking 
behaviour 
 
The novel method of differential labelling of the mitochondrial in the distal and 
proximal chamber was devised in order to determine the origin and directional 
trafficking of the mitochondria as observed in the live mitochondrial imaging of the 
axons as shown in Figure 5a. There have not been any studies prior to this which 
have reported a capability to study this phenomenon or determine the proximal or 
distal origin of the mitochondria upon treatment via live-imaging. Therefore, this 
would make this project the pilot study of the proximal mitochondrial rescue 
mechanism in the field, which was made possible with the use of the compartmental 
neuron culture chamber system as was introduced by Yang et. al. in 2009 [153]. 
Careful control of the volumes in the respective chambers was taken in order to 
eliminate the cross-chamber diffusion of the MitoTracker dyes in each chamber by 
ensuring the axonal chamber has a slightly higher volume of media to prevent 
anterograde diffusion mechanisms of MitoTracker dyes from the proximal chamber 




before treatment has made the study of the source-labelled mitochondrial 
trafficking behaviour apparent with the presence of co-localisation in the merged 
imaged in Figure 5b with the aid of specific colour labelling done with the 
microscope software. The colours chosen to label the different MitoTracker dyes, 
violet for the mitochondria labelled with MitoTracker Deep Red FM and cyan for 
the mitochondria labelled with MitoTracker Orange CMTMRos, were chosen for 
the effect of the result upon combining the two colours upon co-localisation would 
produce a white colouration, when the mitochondria are trafficked from one 
Figure 5. A) Differential labelling of mitochondria of the proximal and distal 
origin. When mitochondria incubated with Mitotracker Orange in the somatic 
chamber (labelled cyan), are trafficked to the axonal chamber, they will be 
exposed to Mitotracker Deep Red (labelled violet), and will develop a white 
colouration. B) Combinatory effect of differentially labelled mitochondria. 
Images of mitochondria labelled with MitoTracker Deep Red FM (violet), 





chamber to the other. This effect would present itself when the trafficked 
mitochondria will either be labelled with the MitoTracker dye present in the media 
of the other chamber or undergoes fusion with distal mitochondria. This effect 
would be a significant milestone towards the investigation of the proximal 
mitochondrial rescue phenomenon which is the defining mechanism in the 
determination of the fate of nerves in mitochondria-related drug-induced 
neurodegeneration.  
As was discussed in the literature review, there is a propensity for PIPN to develop 
in a stocking-and-glove distribution, first characterised in 1993 as afflicting the 
distal extremities most severely with the peripheral neuropathy [159]. This 
phenotype was further investigated as being length-dependent [30, 31], comparing 
the differences in neurodegeneration of the sural nerve and the sciatic nerves in the 
leg. The presence of damaged mitochondria in the axons of the nerves afflicted with 
neuropathy in a study conducted in 2006 [2] brought a new target of investigation 
for PIPN progression mechanisms. Although the presence of the incremental 
damage to mitochondria studied by Flatters and Bennett in 2006 is telling of a 
progressive trend in mitochondrial damage over time as a result of PTX 
neurotoxicity, it was indicative of a key role of mitochondrial damage in the 
progression of PTX-induced neurodegeneration. There can be parallels drawn to 
other models of peripheral neuropathy which also have length dependencies 
towards an increased propensity to neurodegeneration, which are also linked to 




which is partially induced by Highly Active Antiretroviral Therapy (HAART) 
drugs and by HIV proteins, have been found to have a detrimental effect on the 
mitochondrial population, comparing the differences in the mitochondrial 
population in myelinated and unmyelinated neurons. It was proposed that the 
decline of mitochondrial health and lack of mitochondrial interaction with the 
healthier mitochondria from the soma would be detrimental to the axon in the long 
term, thereby exhibiting similar length dependencies of mitochondrial-related 
models of drug-induced neuropathy, due to increased difficulties of interaction of 
mitochondria at distal end of axon to undergo mitochondrial population regulatory 
mechanisms with the PM.  
What made this study effective and novel lies in the ability to induce anterograde 
mitochondrial trafficking for facilitation of the mitochondrial rescue mechanism, 
with the use of a repurposed FDA approved drug FA [115], which can easily be 
translated to the clinical settings without incumbent risks present in the methods 
presented in other study models. The methods reported in the other study models 
to modify mitochondrial trafficking behaviour, are often through modifications to 
the gene expression profile with siRNA, miRNA or knockout models, are often 
imperfect due to the removal of required accessory proteins from the mitochondria-
motor protein setup, such as the knockout of the mitochondrial anchor proteins such 
as Syntaphilin [161]. The use of these methods, while effective in isolating of 
mechanisms to determine an effect on mitochondria trafficking, would be 




crucial in the advancement of the understanding of the mechanisms associated and 
would provide good candidates towards strategies for the regeneration of axons, 
especially in drug-induced neurotoxic conditions such as PIPN. 
3. FA induces anterograde trafficking of mitochondria 
 
It is apparent in Figure 6 that the ratio of PM to DM is affected with FA treatment, 
especially in consideration of the healthy phenotype observed with neurons treated 
with both PTX and FA. With FA treatment alone, the proportion of PM increases 
in comparison to the control by about 1.6 times. This would be indicative of FA’s 
effect on mitochondria trafficking behaviour, with the induction of anterograde 
trafficking of mitochondria from the soma. The total populations of mitochondria 
of each respective treatment condition are normalised to the average numbers of 
mitochondria found in the control. Which would reveal the apparent drop in 
mitochondrial numbers found in the PTX-treated axons, wherein there would have 
been a loss of mitochondrial numbers due to the prior neurodegeneration occurring 
before the imaging conducted at the 24-hour time point. In the respective sites 
chosen for imaging, there would have been limited sites where there would still be 
intact axons, which would disregard the actual amount of axonal degeneration as a 
result of PIPN in the axonal chamber. However, the information obtained from the 
PTX-treated surviving axons is indicative of a phenotype which is required for their 
survival. The ratio of PM to DM in PTX-treated axons is similar to that found in 




shows a healthy phenotype throughout. This would have been indicative of the 
rescue effect which anterograde transport of mitochondria would have had on a 
neurotoxic environment inducing PIPN.  
The mitochondrial population of the FA-PTX treated axons was comparable to the 
control group axons, with a slight drop in mitochondrial numbers comparatively, 
likely the mitigated result of the toxicity of the PTX also present in the culture 
media. However, the axons show a healthy phenotype and negligible blebbing with 
Figure 6. A) Ratio of the number of proximal mitochondria (PM) to the number 
of distal mitochondria (DM). The ratio of PM to DM increased after FA treatment 
compared to the control. Total mitochondrial populations significantly decreased in 
PTX-treated axons, while FA-PTX treatment led to robust recovery of mitochondrial 
numbers compared to PTX-treated axons. Fluocinolone Acetonide treatment (FA); 
Paclitaxel treatment (PTX); Fluocinolone Acetonide and Paclitaxel treatment (FA-
PTX). The data represent mitochondria imaged in 10000 μm2 in the distal axon 
chamber; error bars = s.d.; the data sets were compared with non-parametric 
Kruskal-Wallis with pair-wise Dunn post hoc. *p<0.05. B) Representative images of 
the mitochondria in the axonal chamber for each treatment. Violet and cyan labelled 
mitochondria have distal and proximal origins, respectively.  White labelled mitochondria 




smooth continuous axons, similar in phenotype of the control group axons, which 
is also able to restore the mitochondrial population back to numbers comparable to 
the control. Furthermore, the FA-PTX mitochondrial population shows a similar 
proportion of proximal to DM towards the FA treated axons, indicative of the 
neuroprotective effect which FA-induced anterograde transport of mitochondria 
has to characterise the mitochondrial rescue mechanism.  
Keeping in consideration the benefits which FA might have through 
neuroprotective mechanisms, through abrogation of the neuroinflammatory 
pathways contributing towards neuropathic pain as well as some associated 
pathways assisting with neurodegeneration, the other possible neuroprotective 
pathways which FA could target lie more specifically with the mitochondrial 
proteins. Possibly, through selective inhibitions of the ETC [149] or mPTP 
expression [146] for facilitation of membrane depolarisation, leading to defective 
mitochondria in the axonal mitochondrial population. However, there might be a 
limitation in the parallels drawn with regard to FA’s efficacy on the DRG neurons 
used in the study, due to the lack of studies investigating specifically on the effects 
of FA on neurons other than the pilot study conducted by Centinkaya-Fisgin et. al. 
on the phenotypic effect on DRG neurons with in vitro and in vivo models. The 
study’s experimental outputs for the in vitro model used an ATP concentration 
assay to determine functional ability of the neuron in response to FA treatment in 
PIPN, while the vivo rat model obtained the IENF density from a biopsy of distal 




IENF density [115]. Therefore, this study could be a follow-up investigation into 
the theorised rescue mechanism induced by FA treatment in PIPN. 
The rescue mechanism proposed in the study conducted by Zhou et al. involving 
the promotion of mitochondrial trafficking shed some light towards a possible 
mechanism which could lead to improving the regenerative capabilities of 
axotomised axons [161]. However, it is important to investigate if such a model 
would be applicable to a non-physical trauma to the axons such as drug-induced 
neurodegeneration in PIPN. The rescue mechanism was originally hypothesised 
independently of the results of their study, and founded on the length-dependent 
retrograde neurodegenerative trend observed from the symptoms characterised as a 
stocking-and-glove disease. However, the results published in the study confirms 
that mitochondrial trafficking would be helpful towards compromised axons from 
an energy deficit induced by a physical trauma. The in vitro study outputs from 
Centinkaya-Fisgin et al, the ATP outputs from PIPN is also significantly affected 
and parallels may be drawn with the rescue of an energy deficit drawn from the 
death of the axonal mitochondria from the PIPN model. Therefore, this study would 
be a pilot study of the source specific mitochondria and their associated 
directionality on the trafficking behaviour on these mitochondria as well as 
determining if the induction of mitochondria trafficking was sufficient towards the 





4. FA restores fast mitochondrial transport with PTX toxicity 
 
In the study conducted by Zhou et al., which induced a syntaphilin knockout to 
increase mitochondrial mobility to induce a mitochondrial rescue [161] in an 
axotomy-injury model of axons, it became apparent that mitochondrial mobility is 
very important to the axotomy-injury model, especially with the role that static 
mitochondria have in unmyelinated neurons for energy production for maintenance 
of resting membrane potential. As a result, unmyelinated neuronshave a greater 
proportion of static mitochondria, with a corresponding upregulation of syntaphilin 
in these neurons [162]. Therefore, the susceptibility of these neurons to physical or 
chemical insult is greatly increased, as is apparent in the greater incidence of 
neurodegeneration in PIPN to unmyelinated neurons. While the neuropathic pain is 
independent from the neurodegenerative processes [163], arising instead, from the 
neuroinflammatory effect which PTX has on the myelinated nociceptors, leading 




From Figure 7b and 7c, it is indicative that the velocity profiles of the 
mitochondria population in PTX-treated axons is almost negligible, likely due to 
Figure 7: A) Representative kymographs of different treatment conditions. Anterograde 
trafficking is represented in the left to right direction, while retrograde trafficking is 
represented in the opposite direction. Time-domain is specified in the top-down y-axis. 
Fluocinolone Acetonide treatment (FA); Paclitaxel treatment (PTX); Fluocinolone 
Acetonide and Paclitaxel treatment (FA-PTX)  B) Anterograde mitochondria velocity 
decreased after PTX treatment,  but recovered after FA-PTX treatment. C) 
Retrograde mitochondria velocity is significantly increased in FA-PTX treatment 
compared to both PTX-treated and control group. Fluocinolone Acetonide treatment 
(FA); Paclitaxel treatment (PTX); Fluocinolone Acetonide and Paclitaxel treatment 
(FA-PTX). The data represent the respective average values from n = 20 – 30; error 
bars = s.d.; Significance was determined via non-parametric Kruskal-Wallis with 




the accumulation of microtubules of opposing polarities as well as the 
extensiveness of damaged mitochondria severely hindering the trafficking of the 
mitochondria. With the majority of mitochondrial movement being limited to the 
back-and-forth movement of mitochondria at a fixed spot, represented by the 
dominance of straight lines seen in the kymographs shown in Figure 7a, the long-
distance mitochondrial transport is largely abolished. In contrast, FA treatment with 
PTX is able to restore the presence of long-distance mitochondrial transport as 
shown in the representative kymographs presented in Figure 7a. The fast-
mitochondrial transport mechanism which is required for long distance 
mitochondrial transport for rescue of mitochondria located on the distal ends of the 
axons is restored in FA-PTX treatment.  
Further analysis of the anterograde velocities of the mitochondrial populations 
between the control and FA treatment axons shows that there is no significant 
difference in the pooled results, however, a further breakdown of the anterograde 
velocity data from the mitochondrial population in FA treated axons, there could 
be a sub-division in the mitochondrial populations based on mitochondrial 
velocities as there are two distinct groups of mobile mitochondria. This is an effect 
which could arise as a result of the induction of trafficking of the otherwise static 
mitochondria towards the anterograde direction and this trafficking would have 
reflected as a huge increase in the numbers of slow mitochondrial transport, which 




There is a significant trend of anterograde transport induced with FA treatment, as 
is corroborated in Figure 6a and 8. With Figure 6a reflecting the mitochondrial 
transport which has occurred from the time of treatment until the imaging 
experiment, while Figure 8 reflects the trend of mitochondrial transport observed 
during the imaging experiment. Therefore, the effect which FA has on 
mitochondrial trafficking is apparent with the anterograde mitochondrial velocity 
as compared to the mitochondria in PTX-treated axons (p<0.01) is significantly 
increased.  
Furthermore, in Figure 8, it is shown that FA treatment alone induces a shift in the 
proportion of fast mitochondrial transport towards the anterograde direction, which 
Figure 8: Proportion of anterograde to retrograde fast mitochondrial 
trafficking. FA treatment alone and in a co-treatment with PTX increased the 
proportion of anterograde mitochondrial trafficking. Fluocinolone Acetonide 
treatment (FA); Paclitaxel treatment (PTX); Fluocinolone Acetonide and 
Paclitaxel treatment (FA-PTX). The data represent the respective average values 




is conserved in the FA-PTX treatment axons, while there is no significant difference 
in the proportion of directional mitochondrial transport between the PTX and 
control group, which is indicative that PTX treatment does not influence the 
directionality of the mitochondrial transport. Therefore, the increase in anterograde 
mitochondrial trafficking in the FA-PTX treatment group is the differentiating 
factor which is facilitative of the mitochondrial rescue mechanism from induced 
anterograde mitochondria, when cross-referencing the proportion of PM to DM in 
Figure 6. 
5. FA induces mass mobilisation of mitochondria 
 
There is a significant effect which FA has on mitochondria, similar to the intended 
mobilisation of mitochondria as shown by Zhou et al. study via a Syntaphilin 
knockout model, which was shown to be useful in regenerating axons subjected to 
laser-induced axotomy. In this study, the ratios of the initial numbers of 
mitochondria were compared against the total numbers of mitochondrial tracks 
created by moving mitochondria. In the mitochondrial population in FA treated 
axons, the numbers of moving mitochondria even exceed the number of 
mitochondria initially picked up in the axons as shown in Figure 9, which shows 
that FA induces a robust trafficking behaviour in mitochondria which is strongly 
significant (p<0.01) when compared against the control, in Figure 9. With about 
20 – 40% of the total mitochondrial population composed of mobile mitochondria, 




is indicative that the effect induced in the other drug treatment conditions is 
biologically relevant.  
The proportion of mobile mitochondria in FA-PTX treated axons drops as 
compared to the FA treated axons, likely because of PTX on mitochondrial 
mobility, likely due to PTX’s effect on microtubule stabilisation in hindering 
axonal transport. While the PM rescue is able to restore mitochondrial health, as 
shown in the restoration of mitochondrial population numbers in the FA-PTX 
treatment axons, the effect which PTX has on axonal transport would still likely be 
Figure 9: Proportion of mobile mitochondria to stationary mitochondria. FA 
treatment induced significant increase in mitochondria mobility compared to the 
control, while PTX treatment almost completely abrogated mitochondrial mobility. 
PTX-FA treatment restored mitochondrial mobility. Fluocinolone Acetonide 
treatment (FA); Paclitaxel treatment (PTX); Fluocinolone Acetonide and 
Paclitaxel treatment (FA-PTX). The data represent the respective average values 
from n = 20 – 30; error bars = s.d.;  Significance was determined via non-





affected. This phenomenon, as well as associated processes which are dependent 
upon axonal transport such as mitochondrial functionality which are in turn 
dependent on mitochondrial trafficking capabilities. Therefore, the immediate 
neurodegenerative processes arising from the lack of mitochondrial function is 
likely abrogated in the short-term treatment window, of 24 hours. However, in our 
attempts to replicate the conditions towards the realistic in vivo conditions in the 
body through experimental conditions, a longer treatment window would not be 
relevant due to the presence of continual renal clearance processes to remove the 
drug from the circulation, it would not be likely that the concentration of each drug 
would remain at similar levels after 24 hours at the nerves. Furthermore, it has been 
shown that PTX would be metabolised by the liver into three primary metabolites 
[166], similarly with FA which would have multiple targets of effect in the body 
similar with hydrocortisone treatment, if introduced intravenously.  Furthermore, 
the effects of FA would likely be beneficial with an acute low dose treatment, but 
could lead to undesired side effects if given at too high a dose or over a chronic 
treatment window [146]. Another possible conclusion from this study could be the 
applicability of corticosteroid treatment for neuroprotective effects on 
mitochondria, an extended understanding from a study by Du et al. in 2009 which 
tested the neuroprotective effects which acute low-dose corticosteroid treatment 







Mitochondria’s role and distribution in healthy and diseased neurons have been 
extensively studied, yet the exact mechanisms leading to the respective 
neurodegenerative processes remain inconclusive. The dysfunctions in the 
mitochondrial network are associated with multiple disorders in both the CNS and 
PNS amounting to diseases inclusive of Parkinson’s and Alzheimer diseases as well 
as CIPN. Mitochondria have long been recognised as a potential target for treatment 
strategies through pharmacological interventions or changing gene expression 
levels. However, the study from 2016 by Zhou et al. is the pilot study showing the 
engagement of the mitochondrial network is important in axonal health. In line with 
this approach, the project described in this thesis demonstrates a novel method of 
distinguishing mitochondrial origin – proximal or distal– and tracking 
mitochondrial dynamics in the distal axons. The experimental platform developed 
for this study integrates several well-established techniques: compartmentalised 
neuron culture, mitochondrial staining and time-lapse imaging, creating a relatively 
simple, versatile, but efficient and effective method which can be easily adapted for 
various studies of mitochondrial dynamics. This platform was then used to test a 
hypothesis that fluocinolone acetonide induces trafficking of healthy PM into the 
distal axons through the enhancement of anterograde axonal trafficking, and 
protects axons against paclitaxel induced peripheral neuropathy via maintenance of 
the health of the DM. Therefore, the results of this study could possibly set a new 




However, the fluocinolone acetonide-induced changes in the mitochondrial 
network need to be further investigated to develop a more complete understanding 
of the mitochondrial rescue phenomenon. Henceforth, the development of the novel 
study platform for determination of the source of mitochondria trafficking in the 
rescue phenomenon as well as the demonstration of this rescue phenomenon on 
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